A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Adefovir Dipivoxil

First FDA approval2013-09-03
Generic availableYes · 2 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$3.2M in CY2024 Part D spend4K claims · 713 beneficiaries · 329 plans surveyed

Lowest NADAC
$22.23/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$22.23
Across all dosage forms in distribution.
Highest NADAC
$22.23
Range is tight.
Plans with PA
17 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema7 entries indexed · 4 visible
What is Adefovir Dipivoxil used for?

Adefovir Dipivoxil is a this drug class medication tracked in Medicare Part D.

Is there a generic for Adefovir Dipivoxil?

Yes. 2 ANDAs filed at FDA, 2 generic manufacturers currently shipping.

How much does my plan pay for Adefovir Dipivoxil?

Across 329 Part D plans, Adefovir Dipivoxil averages $22.23/unit (NADAC). Lowest available: $22.23/unit. Highest in distribution: $22.23/unit.

Is Adefovir Dipivoxil on the FDA shortage list?

Adefovir Dipivoxil has been discontinued by its manufacturer(s).

3 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (2 approvals on file) · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.